Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy…

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted eight Sangamo abstracts for presentation at the 25th ASGCT Annual Meeting being held May 16-19, 2022, in-person in Washington, D.C. and in a virtual format. Presentations will focus on the progression of Sangamos pre-clinical programs emerging from its genomic engineering platform.

The data to be presented at ASGCT reflect the diversity and versatility of Sangamos genomic engineering platform, which is being deployed across a range of pre-clinical programs, said Jason Fontenot, Ph.D., Chief Scientific Officer at Sangamo. We look forward to demonstrating the robust pre-clinical knowledge and innovation that continues to emerge from our research efforts, to deliver transformative medicines to patients in need.

Data to be presented at the ASGCT Annual Meeting include an oral presentation of a study looking at Sangamos innovative genetically engineered adeno-associated virus (AAV) capsid platform for delivery to the central nervous system (CNS) after cerebrospinal fluid administration. With protection from the blood-brain barrier, current gene delivery to the CNS continues to be an obstacle. Sangamos AAV capsids are designed to overcome that barrier, providing broad CNS access while minimizing exposure to a patients pre-existing anti-AAV antibodies. Another Sangamo AAV capsid presentation will outline CNS delivery via intravenous administration.

Other presentations at the ASGCT Annual Meeting will showcase how Sangamo is advancing its proprietary zinc finger platform development efforts, including its high-efficiency base-editing program in human cells and its use of zinc finger transcription factors for multiplex engineering of CAR-T cells without imparting changes to the genetic code. Sangamo will also present data from its CAR-Treg cell therapy platform, including outlining advancements in pre-clinical allogeneic Treg engineering.

ASGCT Annual Meeting Presentations and Invited Sessions

Viral Engineering for the Central Nervous System

Genomic Engineering Platform Evolution

Engineered CAR-Treg Platform

All abstracts for the ASGCT Annual Meeting are available on ASGCTs website.

About Sangamo Therapeutics

Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology, and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently dont exist. For more information about Sangamo, visit http://www.sangamo.com.

Sangamo Forward Looking Statements

This press release contains forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, statements relating to Sangamos technologies, the presentation of data from various therapeutic and research programs and the potential of these programs to demonstrate therapeutic benefit and transform the lives of patients. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the research development process, including the results of clinical trials; the regulatory approval process for product candidates; and the potential for technological developments that obviate technologies used by Sangamo. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.

See the original post here:
Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy...